171 related articles for article (PubMed ID: 35252482)
1. Cortical porosity is elevated after a single dose of zoledronate in two rodent models of chronic kidney disease.
Swallow EA; Metzger CE; Chen NX; Wallace JM; Tippen SP; Kohler R; Moe SM; Allen MR
Bone Rep; 2022 Jun; 16():101174. PubMed ID: 35252482
[TBL] [Abstract][Full Text] [Related]
2. Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing.
Swallow EA; Aref MW; Metzger CE; Sacks S; Lehmkuhler DR; Chen N; Hammond MA; Territo PR; Nickolas TL; Moe SM; Allen MR
Bone; 2019 Oct; 127():419-426. PubMed ID: 31299384
[TBL] [Abstract][Full Text] [Related]
3. Reversing cortical porosity: Cortical pore infilling in preclinical models of chronic kidney disease.
Metzger CE; Swallow EA; Stacy AJ; Tippen SP; Hammond MA; Chen NX; Moe SM; Allen MR
Bone; 2021 Feb; 143():115632. PubMed ID: 32927105
[TBL] [Abstract][Full Text] [Related]
4. Cortical porosity development and progression is mitigated after etelcalcetide treatment in an animal model of chronic kidney disease.
Swallow EA; Metzger CE; Newman CL; Chen NX; Moe SM; Allen MR
Bone; 2022 Apr; 157():116340. PubMed ID: 35085840
[TBL] [Abstract][Full Text] [Related]
5. The combination of aging and chronic kidney disease leads to an exacerbated cortical porosity phenotype.
Tippen SP; Metzger CE; Swallow EA; Sacks SA; Wallace JM; Allen MR
Bone; 2022 Jan; 154():116228. PubMed ID: 34624561
[TBL] [Abstract][Full Text] [Related]
6. Strain-specific alterations in the skeletal response to adenine-induced chronic kidney disease are associated with differences in parathyroid hormone levels.
Metzger CE; Swallow EA; Stacy AJ; Allen MR
Bone; 2021 Jul; 148():115963. PubMed ID: 33878503
[TBL] [Abstract][Full Text] [Related]
7. Parathyroid suppression therapy normalizes chronic kidney disease-induced elevations in cortical bone vascular perfusion: a pilot study.
Aref MW; Swallow EA; Metzger CE; Chen N; Moe SM; Allen MR
Osteoporos Int; 2019 Aug; 30(8):1693-1698. PubMed ID: 31069439
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of RANKL improves the skeletal phenotype of adenine-induced chronic kidney disease in mice.
Metzger CE; Kittaka M; LaPlant AN; Ueki Y; Allen MR
JBMR Plus; 2024 Feb; 8(2):ziae004. PubMed ID: 38505524
[TBL] [Abstract][Full Text] [Related]
9. Combining raloxifene and mechanical loading improves bone composition and mechanical properties in a murine model of chronic kidney disease (CKD).
Surowiec RK; Reul ON; Chowdhury NN; Rai RK; Segvich D; Tomaschke AA; Damrath J; Jacobson AM; Allen MR; Wallace JM
Bone; 2024 Jun; 183():117089. PubMed ID: 38575047
[TBL] [Abstract][Full Text] [Related]
10. Elevations in Cortical Porosity Occur Prior to Significant Rise in Serum Parathyroid Hormone in Young Female Mice with Adenine-Induced CKD.
Metzger CE; Swallow EA; Allen MR
Calcif Tissue Int; 2020 Apr; 106(4):392-400. PubMed ID: 31832725
[TBL] [Abstract][Full Text] [Related]
11. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
Meng Y; Zhang H; Li Y; Li Q; Zuo L
Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
[TBL] [Abstract][Full Text] [Related]
12. Adenine-induced chronic kidney disease induces a similar skeletal phenotype in male and female C57BL/6 mice with more severe deficits in cortical bone properties of male mice.
Metzger CE; Swallow EA; Stacy AJ; Allen MR
PLoS One; 2021; 16(4):e0250438. PubMed ID: 33891630
[TBL] [Abstract][Full Text] [Related]
13. Raloxifene Improves Bone Mechanical Properties in Mice Previously Treated with Zoledronate.
Meixner CN; Aref MW; Gupta A; McNerny EMB; Brown D; Wallace JM; Allen MR
Calcif Tissue Int; 2017 Jul; 101(1):75-81. PubMed ID: 28246928
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study.
Sahota O; Narayanasamy M; Bastounis A; Paskins Z; Bishop S; Langley T; Gittoes N; Davis S; Baily A; Holmes M; Leonardi-Bee J
Health Technol Assess; 2024 Apr; 28(21):1-169. PubMed ID: 38634483
[TBL] [Abstract][Full Text] [Related]
15. Adverse mandibular bone effects associated with kidney disease are only partially corrected with bisphosphonate and/or calcium treatment.
Allen MR; Chen NX; Gattone VH; Moe SM
Am J Nephrol; 2013; 38(6):458-64. PubMed ID: 24280830
[TBL] [Abstract][Full Text] [Related]
16. Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.
Moe SM; Chen NX; Newman CL; Organ JM; Kneissel M; Kramer I; Gattone VH; Allen MR
J Bone Miner Res; 2015 Mar; 30(3):499-509. PubMed ID: 25407607
[TBL] [Abstract][Full Text] [Related]
17. Effect of Advanced Glycation End-Products (AGE) Lowering Drug ALT-711 on Biochemical, Vascular, and Bone Parameters in a Rat Model of CKD-MBD.
Chen NX; Srinivasan S; O'Neill K; Nickolas TL; Wallace JM; Allen MR; Metzger CE; Creecy A; Avin KG; Moe SM
J Bone Miner Res; 2020 Mar; 35(3):608-617. PubMed ID: 31743501
[TBL] [Abstract][Full Text] [Related]
18. Evocalcet Rescues Secondary Hyperparathyroidism-driven Cortical Porosity in CKD Male Rats.
Hasegawa T; Tokunaga S; Yamamoto T; Sakai M; Hongo H; Kawata T; Amizuka N
Endocrinology; 2023 Feb; 164(4):. PubMed ID: 36718587
[TBL] [Abstract][Full Text] [Related]
19. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
Li X; Yu L; Asuncion F; Grisanti M; Alexander S; Hensley K; Han CY; Niu QT; Dwyer D; Villasenor K; Stolina M; Dean C; Ominsky MS; Ke HZ; Tomlinson JE; Richards WG
Bone; 2017 Dec; 105():163-172. PubMed ID: 28867373
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo exposure to calcitonin or raloxifene improves mechanical properties of diseased bone through non-cell mediated mechanisms.
Surowiec RK; Saldivar R; Rai RK; Metzger CE; Jacobson AM; Allen MR; Wallace JM
Bone; 2023 Aug; 173():116805. PubMed ID: 37196853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
